Videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/the-continuum-of-care-for-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc@1x.jpg)
The Continuum of Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
- The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt
- Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer View all The Continuum of Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/state-of-the-art-interdisciplinary-management-of-prostate-cancer@1x.jpg)
State-of-the-Art Interdisciplinary Management of Prostate Cancer
- The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer - Matthew Abramowitz
- Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor
- Advances in Staging and Personalized Radiation Therapy for High-Risk Localized Prostate Cancer - Leslie Ballas View all State-of-the-Art Interdisciplinary Management of Prostate Cancer videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/nccn-2024@1x.jpg)
NCCN 2024 Prostate Cancer Guidelines Update
- 2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
- NCCN 2024 Prostate Cancer Guidelines Update: Relugolix Gains Prominence in Treating Metastatic Castration-Sensitive Prostate Cancer - Rashid Sayyid & Zachary Klaassen
- NCCN 2024 Prostate Cancer Guidelines Update: PARP Inhibitors in Focus - Rashid Sayyid & Zachary Klaassen View all NCCN 2024 Prostate Cancer Guidelines Update videos
Enhancing Androgen Blockade in Nonmetastatic Castration-Resistant Prostate Cancer
Genomic Classifier in Prostate Cancer: High-Risk
Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics
EMBARK
Featured Videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/health-policy-in-urological-diseases@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/bladder-cancer@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/esmo-2022@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/apccc-2022@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/localized-prostate-cancer@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/practical-aspects-of-radioligand-therapy-in-the-clinic@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/advanced-prostate-cancer@1x.jpg)
Latest Videos
Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC
APCCC 2024
Recent Conference Coverage
![](https://www.urotoday.com/templates/t3_bs3_blank/images/conferences-images/snmmi-2024@2x.jpg)
- SNMMI 2024: Response Assessment in RPTs for Prostate Cancer: Everyone’s A Winner
- SNMMI 2024: Registrational Trials for PSMA PET
- SNMMI 2024: Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu PSMA Therapy: Comparison to Quantitative SUVmean and Patient Outcomes
![](https://www.urotoday.com/templates/t3_bs3_blank/images/conferences-images/ama-2024@2x.jpg)
- AMA 2024: Updates on Legislation Related Policy Adopted at the AMA 2024 Annual Meeting
- AMA 2024: Updates on Public Health Related Policy Adopted at the AMA 2024 Annual Meeting
- AMA 2024: Updates on Science and Technology Related Policy Adopted at the AMA 2024 Annual Meeting
Recent Physician-Scientist Review Articles
![](https://www.urotoday.com/templates/t3_bs3_blank/images/physician-images/mhspc-coe@2x.jpg)
- Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
- Prostate Radiotherapy for De Novo, Low Volume Metastatic Hormone Sensitive Prostate Cancer: Is There Benefit?
Written by Rashid Sayyid, MD, MSc and Zachary Klaassen, MD, MSc
![](https://www.urotoday.com/templates/t3_bs3_blank/images/physician-images/psma-targeted-therapy-coe@2x.jpg)
- Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer
Written by Zachary Klaassen, MD, MSc, Medical College of Georgia, Augusta, Georgia
Transformative Evidence
EMBARK Trial
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.Serum tumor markers can be a blessing and a curse. After definitive local therapy for prostate cancer, prostate-specific antigen (PSA) is quite sensitive and specific, and can detect micrometastatic disease well before any radiographic or symptomatic evidence of disease. When biochemical recurrence (BCR) occurs, early detection can guide curative-intent salvage therapies such as salvage radiation.
Read MoreARASENS Trial
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.In the ARASENS trial (NCT02799602), darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% (HR, 0.68; 95% CI, 0.57-0.80; P < .0001) compared with placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We present efficacy and safety of darolutamide versus placebo in Black patients from ARASENS.
Read MoreTrials in Progress
Pivot-006 Trial
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC– 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint of the phase 2 study
Read More
CLARIFY Trial
First patient dosed in Clarity’s registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA- First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial, CLARIFY.
- The aim of the CLARIFY trial is to detect regional nodal metastases in participants with prostate cancer prior to radical prostatectomy.
- Final results from the CLARIFY trial are intended to provide sufficient evidence to support an application to the FDA for the approval of the 64Cu-SAR-bisPSMA product in pre-prostatectomy patients.